Skip to content
OpenCapital
Get started

Syndax Pharmaceuticals SNDX Royalty Interest Financing Liability Less Current Portion

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K—
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.77B+95.0%

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept sndx:RoyaltyInterestFinancingLiabilityLessCurrentPortion.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Syndax Pharmaceuticals's royalty interest financing liability less current portion?
Syndax Pharmaceuticals (SNDX) reported royalty interest financing liability less current portion of $343.97M in Q1 2026.
How has Syndax Pharmaceuticals's royalty interest financing liability less current portion changed year-over-year?
Syndax Pharmaceuticals's royalty interest financing liability less current portion increased by 4.3% year-over-year, from $329.64M to $343.97M.